Quantcast

Latest Centocor Stories

2014-08-14 23:11:39

BioScience Laboratories, Inc. can now screen psoriasis drug formulations in their Skin Technology Center utilizing an in-vitro human psoriasis tissue model. Bozeman, MT (PRWEB) August 14, 2014 Psoriasis is an immune-mediated disease that results in deep skin cells rising rapidly to the surface in just days, rather than the normal month. Extra skin cells build up and form thick, silvery scales and dry red patches that often present on the elbows, knees, scalp, back, face, palms and feet of...

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-07-24 16:24:29

Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis....

2014-07-21 16:26:51

NEW BRUNSWICK, N.J., July 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has approved the repurchase of up to $5 billion of the company's common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available for...

2014-06-19 08:28:47

-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections -- NEW BRUNSWICK, N.J., June 19, 2014 /PRNewswire/ -- Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across...

2014-06-14 23:01:22

The Firm is representing hundreds of women who have filed vaginal mesh lawsuits against Johnson & Johnson’s Ethicon unit in state and federal courts. New York, New York (PRWEB) June 14, 2014 As the litigation surrounding vaginal mesh complications (http://www.transvaginalmeshlawsuithelp.com/transvaginal-mesh-complications/) allegedly caused by devices used to treat pelvic organ prolapse and stress urinary incontinence continues to grow, Bernstein Liebhard LLP notes that the Illinois...

2014-05-22 08:30:31

- More than 30 major product filings planned through 2016 NEW BRUNSWICK, N.J., May 22, 2014 /PRNewswire/ -- At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets. Creating Value through...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-04-29 08:36:39

NEW BRUNSWICK, N.J., April 29, 2014 /PRNewswire/ -- Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership's Global Drug Facility (GDF), to facilitate access to the Company's anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'